Pulmonary Hypertension in Interstitial Lung Disease: A Systematic Review and Meta-Analysis.

Autor:	Ang HL; Royal Melbourne Hospital, VIC, Australia; Institute for Breathing and Sleep, VIC, Australia., Schulte M; Institute for Breathing and Sleep, VIC, Australia., Chan RK; Department of Cardiology, Western Health, St. Albans, VIC, Australia., Tan HH; Royal Sussex County Hospital, Brighton, England., Harrison A; Department of Respiratory and Sleep Disorders Medicine, Western Health, St. Albans, VIC, Australia., Ryerson CJ; University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, Vancouver, BC, Canada., Khor YH; Institute for Breathing and Sleep, VIC, Australia; School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, VIC, Australia. Electronic address: yet.khor@monash.edu.
Jazyk:	angličtina
Zdroj:	Chest [Chest] 2024 Oct; Vol. 166 (4), pp. 778-792. Date of Electronic Publication: 2024 May 29.
DOI:	10.1016/j.chest.2024.04.025
Abstrakt:	Background: Pulmonary hypertension (PH) is a key complication in interstitial lung disease (ILD), with recent therapeutic advances. Research Question: What are the diagnostic evaluation, epidemiologic features, associated factors, prognostic significance, and outcome measures in interventional trials for PH in patients with ILD in the current literature? Study Design and Methods: The Ovid MEDLINE, Embase, and CENTRAL databases were searched for original research evaluating PH in participants with ILD of any cause. The definition of PH was based on the investigators' criteria. Results: Three hundred two studies were included, with varying diagnostic evaluations used to define PH. Commonly used diagnostic tests were right heart catheterization (56%) and transthoracic echocardiography (50%). The pooled prevalence for PH in general populations with ILD was 36% (95% CI, 30%-42%) using right heart catheterization and 34% (95% CI, 29%-38%) using transthoracic echocardiography. Lower diffusion capacity of the lungs for carbon monoxide, worse oxygenation status, reduced exercise capacity, increased pulmonary artery to aorta ratio and pulmonary artery diameter, and elevated serum brain natriuretic peptide consistently were associated with the presence of PH in at least 60% of reported studies. The presence of PH was associated with increased symptom burden and worse prognosis. Outcome measures in interventional trials of PH in ILD focused on changes in pulmonary vascular hemodynamics and 6-min walk distance. Interpretation: PH is a common complication in ILD with significant health impacts. A standardized definition with prospective evaluation of risk-stratified assessments for PH using identified associated risk factors is warranted. Our findings provide an evidence base for validation as surrogate end points in future PH interventional trials in ILD. Trial Registry: International Prospective Register of Systematic Reviews; No.: CRD42021255394; URL: https://www.crd.york.ac.uk/prospero/. Competing Interests: Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: Y. H. K. reports fellowship support from an NHMRC Investigator Grant, Austin Medical Research Foundation, and Royal Australasian College of Physicians, and grants from Boehringer Ingelheim during the conduct of the study. C. J. R. reports grants from Boehringer Ingelheim during the conduct of the study, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Hoffmann-La Roche, personal fees from Veracyte, personal fees from Pliant Therapeutics, personal fees from Astra Zeneca, and personal fees from Cipla Ltd. outside the submitted work. None declared (H. L. A., M. S., R. K. C., H. H. T., A. H.). (Copyright © 2024 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu